[ad_1]
AstraZeneca PLC (NASDAQ:Azn) Q2 2025 Earnings Convention Name July 29, 2025 9:00 AM ET
Firm Contributors
Andrew P. Barnett – Head of Investor Relations
Aradhana Sarin – CFO & Government Directorro
David Fredrickson – Government Vice-President of Oncology Haematology Enterprise Unit
Iskra Reic – Government Vice President of Worldwide
Marc dunory – CEO of alexion & Chief Technique Officer
Pascal Claude Roland Soriot – CEO & Government Director
Ruud Dobber – Government Vice-President of BioPharmaceuticals Enterprise Unit
Sharon Barr – Government Vice-President of BioPharmaceuticals R&D
Susan Mary Galbraith – Government Vice President of Oncology R&D
Convention Name Contributors
Gonzalo Artiach Castanon – Danske Financial institution A/S, Analysis Division
James Daniel Gordon – JPMorgan Chase & Co, Analysis Division
Luisa Caroline Hector – Joh. Berenberg, Gossler & Co. KG, Analysis Division
Matthew Weston – UBS Funding Financial institution, Analysis Division
Michael Leuchten – Unidetified Firm
Peter Verdult – BNP Paribas Exane, Analysis Division
Rajan Sharma – Goldman Sachs Group, Inc., Analysis Division
Sachin Jain – BofA Securities, Analysis Division
Sarita Kapila – Morgan Stanley, Analysis Division
Seamus Christopher Fernandez – Guggenheim Securities, LLC, Analysis Division
Operator
Good afternoon, and welcome to AstraZeneca’s H1 and Q2 2025 webinar for buyers and analysts. Earlier than I hand over to AstraZeneca, I might prefer to learn the protected harbor assertion. The corporate intends to make the most of the protected harbor provisions of the USA Non-public Securities Litigation Reform Act of 1995. Contributors on this name might make forward-looking statements with respect to the operations and monetary efficiency of AstraZeneca. Though we imagine our expectations are based mostly on cheap assumptions, by their very nature, forward-looking statements contain dangers and uncertainties and could also be influenced by elements that might trigger precise outcomes to vary materially from these expressed or implied by these forward-looking statements.
Any forward-looking statements made on this name
[ad_2]
Supply hyperlink